La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ligand Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 2/6

Gli utili di Ligand Pharmaceuticals sono diminuiti a un tasso medio annuo di -58.9%, mentre il settore Pharmaceuticals ha visto gli utili diminuire a un tasso medio annuo di 0.2%. I ricavi sono cresciuti crescere a un tasso medio annuo di 0.5%. Il ritorno sul capitale proprio di Ligand Pharmaceuticals è 5.4% e ha margini netti di 31.6%.

Informazioni chiave

-58.9%

Tasso di crescita degli utili

-54.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	0.5%
Rendimento del capitale proprio	5.4%
Margine netto	31.6%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17

Ripartizione dei ricavi e delle spese

Come Ligand Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:LGND Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	133	42	59	0
31 Mar 24	118	96	53	0
31 Dec 23	131	54	53	0
30 Sep 23	154	21	68	10
30 Jun 23	180	41	68	10
31 Mar 23	204	51	69	0
31 Dec 22	196	-5	70	0
30 Sep 22	183	23	46	0
30 Jun 22	188	27	44	0
31 Mar 22	223	45	46	0
31 Dec 21	242	76	47	0
30 Sep 21	275	68	49	0
30 Jun 21	252	48	51	0
31 Mar 21	208	39	47	0
31 Dec 20	164	7	39	0
30 Sep 20	143	-16	45	0
30 Jun 20	126	-25	39	0
31 Mar 20	110	-61	40	0
31 Dec 19	120	629	42	0
30 Sep 19	153	594	43	0
30 Jun 19	174	677	43	0
31 Mar 19	239	764	41	0
31 Dec 18	251	143	38	0
30 Sep 18	242	179	34	0
30 Jun 18	230	120	32	0
31 Mar 18	168	53	29	0
31 Dec 17	141	13	29	0
30 Sep 17	129	16	28	0
30 Jun 17	117	9	27	0
31 Mar 17	109	-3	28	0
31 Dec 16	109	-2	28	0
30 Sep 16	92	7	27	0
30 Jun 16	88	205	25	0
31 Mar 16	87	235	25	0
31 Dec 15	72	230	25	0
30 Sep 15	74	231	24	0
30 Jun 15	71	33	25	0
31 Mar 15	63	11	23	0
31 Dec 14	65	12	23	0
30 Sep 14	56	7	21	0
30 Jun 14	54	8	19	0
31 Mar 14	53	10	19	0
31 Dec 13	49	9	18	0
30 Sep 13	48	10	18	0

Guadagni di qualità: LGND ha un grande una tantum guadagno di $74.1M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2024.

Margine di profitto in crescita: Gli attuali margini di profitto netti di LGND (31.6%) LGND sono più alti rispetto allo scorso anno (22.8%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di LGND sono diminuiti del 58.9% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di LGND nell'ultimo anno ( 2.8% ) supera la media quinquennale ( -58.9% all'anno).

Guadagni vs Settore: La crescita degli utili LGND nell'ultimo anno ( 2.8% ) non ha superato quella del settore Pharmaceuticals 13%.

Ligand Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 2/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for the Full Year of 2024

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into an agreement to acquire APEIRON Biologics AG for $128 million.

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Chief Financial Officer notifies of intention to sell stock

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

President & COO recently sold US$1.5m worth of stock

Consensus EPS estimates increase by 199%

Chief Legal Officer & Secretary notifies of intention to sell stock

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer

Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022

Price target decreased to US$149

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt